Clinical evaluation of total and high-avidity anti-dsDNA antibody assays for the diagnosis of systemic lupus erythematosus
The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Background: This study evaluated the diagnostic performances of total and high-avidity (HA) anti-dsDNA enzyme immunoassays (EIA) in Chinese systemic lupus erythematosus (SLE) patients. Methods: A total of 410 serum samples from 217 SLE patients, 54 patients with other systemic autoimmune diseases, and 139 healthy subjects were tested on total and HA anti-dsDNA EIA, as well as three commercial in vitro diagnostic kits: BioPlex 2200 ANA Screen, Kallestad anti-dsDNA EIA, and Crithidia Lucilae IFA. The disease activities of SLE patients were assessed using the modified SLE Disease Activity Index. The diagnostic performances of each assay were analyzed using Analyse-it software. Results: The diagnostic performances of the total and HA anti-dsDNA EIA kits were comparable to other commercially available in vitro diagnostic assays. Receiver operating characteristic curve analysis demonstrated an area under the curve ranging from 0.85 to 0.89, with the total anti-dsDNA kit demonstrating the highest sensitivity and the HA kit showing higher specificity. An overall agreement of >90% was observed between the total and HA anti-dsDNA EIA kits and commercially available quantitative anti-dsDNA kits. The ratio of HA to total anti-dsDNA antibody was significantly higher among SLE patients with active disease status and/or kidney damage. All assays exhibited a significant correlation with disease activity and multiple clinical manifestations. Conclusions: While the clinical performances of various anti-dsDNA assays showed adequate agreements, the BioPlex 2200 anti-dsDNA assay demonstrated the highest positive likelihood ratio and odds ratio. The HA anti-dsDNA EIA kit in association with the total anti-dsDNA kit provided superior performance in SLE diagnosis and monitoring disease activity.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“ELISAs targeting the high avidity antibodies showed higher specificity compared to the low avidity ELISAs [39], [64].”
From Laboratory evaluation of anti-dsDNA antibodies. (2022) · cites this paper as [64]
In the citing paper
“Mainly assays that detect high avidity antibodies showed a correlation with disease activity or lupus nephritis [45], [58], [64].”
From Laboratory evaluation of anti-dsDNA antibodies. (2022) · cites this paper as [64]
In the citing paper
“Finally, Yuan et al. compared CLIFT, ELISA and multiplexed immunoassay at a cutoff that corresponded to a specificity of 95% and found the highest sensitivities for ELISA and multiplexed immunoassay [64].”
From Laboratory evaluation of anti-dsDNA antibodies. (2022) · cites this paper as [64]
In the citing paper
“Yuan et al. reported the lowest AUC for CLIFT (compared to ELISA and multiplexed assay) [64].”
From Laboratory evaluation of anti-dsDNA antibodies. (2022) · cites this paper as [64]
In the citing paper
“Antidouble-stranded DNA (anti-dsDNA) autoantibodies play a pivotal role in the diagnosis and follow-up of SLE1–3 and are related to the development of lupus nephritis.4 5”
From Longitudinal study of patients with discrepant results in CLIFT and a solid-phase dsDNA antibody assay: Does a gold standard dsDNA assay exist? (2023) · cites this paper as [1]
Citations
Cites
The 1982 revised criteria for the classification of systemic lupus erythematosus
Tan, E. M., Cohen, A. S., Fries, J. F., Masi, A. T., Mcshane, D. J., Rothfield, N. F., Schaller, J. G., Talal, N., & Winchester, R. J. (1982) · Arthritis & Rheumatism · doi:10.1002/art.1780251101 · Cited by 14,519
Hochberg, M. C. (1997) · Arthritis & Rheumatism · doi:10.1002/art.1780400928 · Cited by 11,409
Derivation of the sledai. A disease activity index for lupus patients
Bombardier, C., Gladman, D. D., Urowitz, M. B., Caron, D., Chang, C. H., Austin, A., Bell, A., Bloch, D. A., Corey, P. N., Decker, J. L., et al. (1992) · Arthritis & Rheumatism · doi:10.1002/art.1780350606 · Cited by 4,570
DeGiorgio, L. A., Konstantinov, K. N., Lee, S. C., Hardin, J. A., Volpe, B. T., & Diamond, B. (2001) · Nature Medicine · doi:10.1038/nm1101-1189 · Cited by 798
Sherer, Y., Gorstein, A., Fritzler, M. J., & Shoenfeld, Y. (2004) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2004.07.002 · Cited by 578
Ter Borg, E. J., Horst, G., Hummel, E. J., Limburg, P. C., & Kallenberg, C. G. M. (1990) · Arthritis & Rheumatism · doi:10.1002/art.1780330505 · Cited by 572
Winfield, J. B., Faiferman, I., & Koffler, D. (1977) · Journal of Clinical Investigation · doi:10.1172/jci108626 · Cited by 405
The use of laboratory tests in the diagnosis of SLE
Egner, W. (2000) · Journal of Clinical Pathology · doi:10.1136/jcp.53.6.424 · Cited by 316
Prevention of relapses in systemic lupus erythematosus
Bootsma, H., Spronk, P., de Boer, G., Limburg, P., Kallenberg, C., Derksen, R., Wolters-Dicke, J., Gmelig-Meyling, F., Kater, L., & Hermans, J. (1995) · The Lancet · doi:10.1016/s0140-6736(95)90114-0 · Cited by 290
Anti‐dsdna and complement profiles as prognostic guides in systemic lupus erythematosus
Swaak, A. J. G., Aarden, L. A., Statius Eps, L. W. V., & Feltkamp, T. E. W. (1979) · Arthritis & Rheumatism · doi:10.1002/art.1780220304 · Cited by 284
Research works printed but not linked: 4
- Neogi T, 2006, J Rheumatol, 33, 72
- Ghirardello A, 2011, Clin Exp Rheumatol, 29, 50
- Smeenk RJ, 2002, Clin Exp Rheumatol, 20, 294
- Suh-Lailam BB, 2011, Int J Clin Exp Pathol, 4, 748
Cited by
Laboratory evaluation of anti-dsDNA antibodies.
Cockx, M., Van Hoovels, L., De Langhe, E., Lenaerts, J., Thevissen, K., Persy, B., Bonroy, C., Vercammen, M., & Bossuyt, X. (2022) · Clinica Chimica Acta · doi:10.1016/j.cca.2021.12.029 · Cited by 30
Trujillo Aguilera, A., Bernardo Serrano, R., Navas, A., Alcaide Molina, J., Alvarez Romero, P., & Jurado Roger, A. (2023) · Lupus Science & Medicine · doi:10.1136/lupus-2023-000984 · Cited by 6
Ricchiuti, V., Obney, J., Holloway, B., Aure, M. A., Shapiro, M., Bentow, C., & Mahler, M. (2025) · Diagnostics · doi:10.3390/diagnostics15192430 · Cited by 3
“This variability may be due to differences in antigen sources (native vs. synthetic), assay design, or result interpretation, even if the assays are fully automated [13].”
Metadata
- Authors
- Yuan, W., Cao, H., Wan, P., Shi, R., Zhou, S., & Zheng, J.
- Affiliations
- Shanghai Jiao Tong University (CN)
- Bio-Rad (United States) (US)
- Corresponding author
- Zhou, S
- Zheng, J
- Venue
- Lupus
- Publisher
- SAGE Publications
- Published
- 2019-09-30
- Volume
- 28
- Issue
- 12
- Pages
- 1387-1396
- ISSN
- 0961-2033 (ISSN-L)
- 1477-0962
- OpenAlex
- W2979088984
- Cited by
- 15
- References
- 41
- Citations by year
- 2026: 3 · 2025: 3 · 2023: 3 · 2022: 1 · 2021: 4 · 2020: 1
- FWCI
- 1.14
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Lupus (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Key Clinical Specialty (2012649)
- Topics
- Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
- Health Sciences › Medicine › Rheumatology › Systemic Sclerosis and Related Diseases
- Health Sciences › Medicine › Rheumatology › Vasculitis and related conditions
- Keywords
- systemic lupus erythematosus, anti-dsDNA antibodies, enzyme immunoassay, diagnostic accuracy, disease activity, kidney injury, Chinese patients
- MeSH terms
- Adult, Aged, Antibody Affinity, Antibodies, Antinuclear, Autoantibodies, Autoimmune Diseases, Female, Humans, Lupus Erythematosus, Systemic, Male, Middle Aged, Reagent Kits, Diagnostic, Sensitivity and Specificity, Asian People
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical evaluation of total and high-avidity anti-dsDNA antibody assays for the diagnosis of systemic lupus erythematosus. https://app.cochat.ai/papers/10.1177/0961203319877243
- The paper
- Yuan, W., Cao, H., Wan, P., Shi, R., Zhou, S., & Zheng, J. (2019). Clinical evaluation of total and high-avidity anti-dsDNA antibody assays for the diagnosis of systemic lupus erythematosus. Lupus. https://doi.org/10.1177/0961203319877243
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.